Psoriasis

Tapinarof is a first-in-class topical steroid-free aryl hydrocarbon receptor antagonist intended to mitigate the symptoms of plaque psoriasis.

Indications for adalimumab include ankylosing spondylitis, Crohn disease, chronic plaque psoriasis, juvenile idiopathic arthritis, moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.

Tildrakizumab-asmn is a humanized IgG1/k monoclonal anti-IL-23 antibody indicated for the treatment of adults with moderate-to-severe plaque psoriasis.

Long-term extension trial results show a consistent safety profile and durable efficacy for the treatment of adults with the skin condition.

The results of a network analyses show that the elevated potential of contracting the virus is also linked to infliximab and tofacitinib, as well as several combination treatments.

The phase 3, multicenter, randomized, double-blinded, comparative clinical study was evaluating the efficacy and safety of ABP 654 compared with ustekinumab in adult patients with moderate to severe plaque psoriasis.

Deucravacitinib is a possible solution for patients with psoriasis who wish to have the convenience of an oral medication.

Johnson & Johnson’s Janssen Pharmaceutical Companies subsidiary’s post-hoc analysis of Tremfya demonstrates clinically significant improvements.

Oral apremilast achieved a clinically meaningful and statistically significant improvement in the primary endpoint of the modified static Physician’s Global Assessment of Genitalia response.

The drug is the first and only oral therapy approved for the treatment of adult patients who are candidates for either phototherapy or systemic therapy.

The study enrolled 214 patients, with 105 randomized to a risankizumab injection every 4 weeks over a 24-week period, while 109 patients received a placebo.

The main factors behind the vaccine hesitancy are the potential adverse effects post-vaccination and effect on their autoimmune conditions, as well as lack of trial data, an analysis shows.